Vical Announces Issuance of Key Naked DNA Vaccine Patent

Apr 10, 2001, 01:00 ET from Vical Incorporated

    SAN DIEGO, April 10 /PRNewswire/ -- Vical Incorporated (Nasdaq:   VICL)
 today announced the issuance of U.S. Patent No. 6,214,804, which expands the
 company's broad ownership of naked DNA gene delivery technologies by including
 administration of naked DNA into any tissue for the purpose of inducing an
 immune response.
     This patent effectively renews and reinforces Vical's previously issued
 patent covering naked DNA injection into muscle or skin to stimulate an immune
 response systemically.  Moreover, it generically covers both systemic and
 local administration of naked DNA vaccines.  Local administration may alter
 the characteristics of the body's immune response, providing potentially
 improved immunity against certain diseases.  For example, naked DNA
 vaccination via pulmonary (lung) or intranasal delivery may prove beneficial
 for certain diseases which have so far proven unresponsive to conventional
 vaccination.  Vical has more than 400 issued or pending patents worldwide.
     Vical's novel method for delivering genes into cells in the body is
 different from current medicine because it delivers DNA to the cell through a
 ring of genetic material called a plasmid, or "naked DNA."  Naked DNA is
 different from other gene delivery techniques because it doesn't use viruses
 to deliver the genetic material -- the genes are "virus-bare" or "naked."
 Because naked DNA delivery does not involve administration of potentially
 infectious viruses, it avoids any negative side effects typically associated
 with viral-based delivery methods for vaccines or therapeutics.
     Vical's President and Chief Executive Officer, Vijay B. Samant, said, "We
 are pleased to expand our patent estate with this key addition.  Naked DNA is
 able to cause vital stimulation of the human immune system and we are
 delighted by the possibilities this patent opens to us in our search for new
 and better treatments for mankind."
     Vical Incorporated, The Naked DNA Company(TM), is focused on the
 development of pharmaceutical product candidates based on its patented gene
 delivery technology.  A number of therapeutic and vaccine product candidates
 are currently under development for the prevention or treatment of cancer,
 infectious diseases and metabolic disorders by Vical and its collaborative
 partners, including Merck & Co., Pfizer Inc., Aventis Pasteur, Aventis Pharma,
 Human Genome Sciences, Centocor Inc., Merial and Boston Scientific
 Corporation.  Allovectin-7(R), which uses a lipid-DNA complex to help the
 immune system recognize and attack cancer cells, is in Phase II and Phase III
 testing in certain patients with metastatic melanoma and in Phase II testing
 in patients with head and neck cancer.  Leuvectin(TM), which uses a lipid-DNA
 complex to stimulate an immune response against cancer cells, is in Phase II
 testing in patients with kidney cancer and prostate cancer.  Vaxid, a naked
 DNA vaccine to prevent relapse of B-cell lymphoma, is in Phase I/II testing.
 In collaboration with the National Cancer Institute, a naked DNA vaccine to
 treat metastatic melanoma is in Phase I/II testing.  If you are interested in
 any of Vical's clinical trials, please see our website at www.vical.com, or
 contact Tammy Boyce by phone at 858/646-1120 or by e-mail at tboyce@vical.com.
 
     This press release contains forward-looking statements subject to risks
 and uncertainties that could cause actual results to differ materially from
 those projected.  Forward-looking statements include statements about the
 company's focus, collaborative partners, product candidates, and developmental
 status.  Risks and uncertainties include whether any product candidates will
 be shown to be safe and efficacious in clinical trials, the timing of clinical
 trials, whether Vical or its collaborative partners will seek or gain approval
 to market any product candidates, and additional risks set forth in the
 company's filings with the Securities and Exchange Commission.  These
 forward-looking statements represent the company's judgment as of the date of
 this release.  The company disclaims, however, any intent or obligation to
 update these forward-looking statements.
 
     For news releases and other information about the company, visit the Vical
 web site at www.vical.com.
 
 

SOURCE Vical Incorporated
    SAN DIEGO, April 10 /PRNewswire/ -- Vical Incorporated (Nasdaq:   VICL)
 today announced the issuance of U.S. Patent No. 6,214,804, which expands the
 company's broad ownership of naked DNA gene delivery technologies by including
 administration of naked DNA into any tissue for the purpose of inducing an
 immune response.
     This patent effectively renews and reinforces Vical's previously issued
 patent covering naked DNA injection into muscle or skin to stimulate an immune
 response systemically.  Moreover, it generically covers both systemic and
 local administration of naked DNA vaccines.  Local administration may alter
 the characteristics of the body's immune response, providing potentially
 improved immunity against certain diseases.  For example, naked DNA
 vaccination via pulmonary (lung) or intranasal delivery may prove beneficial
 for certain diseases which have so far proven unresponsive to conventional
 vaccination.  Vical has more than 400 issued or pending patents worldwide.
     Vical's novel method for delivering genes into cells in the body is
 different from current medicine because it delivers DNA to the cell through a
 ring of genetic material called a plasmid, or "naked DNA."  Naked DNA is
 different from other gene delivery techniques because it doesn't use viruses
 to deliver the genetic material -- the genes are "virus-bare" or "naked."
 Because naked DNA delivery does not involve administration of potentially
 infectious viruses, it avoids any negative side effects typically associated
 with viral-based delivery methods for vaccines or therapeutics.
     Vical's President and Chief Executive Officer, Vijay B. Samant, said, "We
 are pleased to expand our patent estate with this key addition.  Naked DNA is
 able to cause vital stimulation of the human immune system and we are
 delighted by the possibilities this patent opens to us in our search for new
 and better treatments for mankind."
     Vical Incorporated, The Naked DNA Company(TM), is focused on the
 development of pharmaceutical product candidates based on its patented gene
 delivery technology.  A number of therapeutic and vaccine product candidates
 are currently under development for the prevention or treatment of cancer,
 infectious diseases and metabolic disorders by Vical and its collaborative
 partners, including Merck & Co., Pfizer Inc., Aventis Pasteur, Aventis Pharma,
 Human Genome Sciences, Centocor Inc., Merial and Boston Scientific
 Corporation.  Allovectin-7(R), which uses a lipid-DNA complex to help the
 immune system recognize and attack cancer cells, is in Phase II and Phase III
 testing in certain patients with metastatic melanoma and in Phase II testing
 in patients with head and neck cancer.  Leuvectin(TM), which uses a lipid-DNA
 complex to stimulate an immune response against cancer cells, is in Phase II
 testing in patients with kidney cancer and prostate cancer.  Vaxid, a naked
 DNA vaccine to prevent relapse of B-cell lymphoma, is in Phase I/II testing.
 In collaboration with the National Cancer Institute, a naked DNA vaccine to
 treat metastatic melanoma is in Phase I/II testing.  If you are interested in
 any of Vical's clinical trials, please see our website at www.vical.com, or
 contact Tammy Boyce by phone at 858/646-1120 or by e-mail at tboyce@vical.com.
 
     This press release contains forward-looking statements subject to risks
 and uncertainties that could cause actual results to differ materially from
 those projected.  Forward-looking statements include statements about the
 company's focus, collaborative partners, product candidates, and developmental
 status.  Risks and uncertainties include whether any product candidates will
 be shown to be safe and efficacious in clinical trials, the timing of clinical
 trials, whether Vical or its collaborative partners will seek or gain approval
 to market any product candidates, and additional risks set forth in the
 company's filings with the Securities and Exchange Commission.  These
 forward-looking statements represent the company's judgment as of the date of
 this release.  The company disclaims, however, any intent or obligation to
 update these forward-looking statements.
 
     For news releases and other information about the company, visit the Vical
 web site at www.vical.com.
 
 SOURCE  Vical Incorporated